Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ATF4 | P18848 | 5/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25638991 | 0.84 | HSD11B1 (0.41) | PKMATF4NPSR1ALDH1A1MEN1 | |
| SCHEMBL25638999 | 0.79 | PKM (0.43) | PKMATF4MEN1KMT2A | |
| SCHEMBL25639002 | 0.73 | ATF4 (0.57) | ATF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL19747457 | 0.70 | PKM (0.44) | PKM | |
| SCHEMBL19920585 | 0.68 | MEN1 (0.40) | PKMMEN1KMT2A | |
| SCHEMBL26701380 | 0.68 | PKM (0.52) | PKMKMT2A | |
| SCHEMBL20610358 | 0.66 | ATF4 (0.86) | ATF4NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL26091268 | 0.66 | PKM (0.50) | PKMNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL20722058 | 0.65 | ATF4 (0.53) | ATF4NPSR1ALDH1A1MEN1MAPT | |
| SCHEMBL23357896 | 0.64 | ATF4 (0.44) | ATF4NPSR1ALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192712-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192712-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | PKM 575/4885ATF4 1/4885NPSR1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.